Development and Validation of a High‐Quality Composite Real‐World Mortality Endpoint-Reference-Cited by-同舟云学术

Development and Validation of a High‐Quality Composite Real‐World Mortality Endpoint

Published:2018-05-14 Issue:6 Volume:53 Page:4460-4476
ISSN:0017-9124
Container-title:Health Services Research
language:en
Short-container-title:Health Serv Res

Author:

Curtis Melissa D.¹,Griffith Sandra D.¹,Tucker Melisa¹,Taylor Michael D.²,Capra William B.²,Carrigan Gillis²,Holzman Ben¹,Torres Aracelis Z.¹,You Paul¹,Arnieri Brandon²,Abernethy Amy P.¹^ORCID

Affiliation:

1. Flatiron Health New York NY

2. Genentech South San Francisco CA

Publisher

Wiley

Subject

Health Policy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1475-6773.12872

Reference10 articles.

1. Demise of a vital resource

2. Utility of the National Death Index for Ascertainment of Mortality among Cancer Prevention Study II Participants

3. A Primer and Comparative Review of Major U.S. Mortality Databases. Ann;Cowper D. C.;Epidemiology,2002

4. Consequences for Healthcare Quality and Research of the Exclusion of Records From the Death Master File

5. Real-world Data for Clinical Evidence Generation in Oncology

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC;CLIN LUNG CANCER;2024

2. 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC;Clinical Lung Cancer;2024-09

3. Trends in the Completeness and Validity of Sources of Death Data Against the National Death Index From 2010 to 2018;Pharmacoepidemiology and Drug Safety;2024-08

4. Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-08

5. Real-world Uptake of Enfortumab Vedotin plus Pembrolizumab after US Food and Drug Administration Approval Among Patients with Advanced Urothelial Cancer;European Urology;2024-08